LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

Home・Akcijų sąrašas・Actinium Pharmaceuticals Inc

Actinium Pharmaceuticals Inc

Uždarymo kaina

1.5 3.45

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

1.49

Max

1.5

Pagrindiniai rodikliai
By Trading Economics
Pajamos	1.7M -5.1M
Pardavimai	90K 90K
Pelno marža	-5,701.111
Darbuotojai	25
EBITDA	2.6M -4.9M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+297.35% upside

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	2.2M 44M
Ankstesnė atidarymo kaina	-1.95
Ankstesnė uždarymo kaina	1.5

Actinium Pharmaceuticals Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-12-13 00:04; UTC

Įsigijimai, susijungimai, perėmimai

Intel in Talks to Acquire SambaNova in Deal Valued at $1.6 Billion, Bloomberg Reports, Citing Sources

2025-12-12 16:42; UTC

Įsigijimai, susijungimai, perėmimai

FTC Sues to Block Henkel's $725 Million Deal for Liquid Nails From PE Firm -- 2nd Update

2025-12-13 16:48; UTC

Įsigijimai, susijungimai, perėmimai

How the War to Win Warner Bros. Discovery Will Be Won -- Barrons.com

2025-12-13 08:00; UTC

Įsigijimai, susijungimai, perėmimai

How the War to Win Warner Bros. Discovery Will Be Won -- Barrons.com

2025-12-13 07:00; UTC

Įsigijimai, susijungimai, perėmimai

A Chubb/AIG Deal Could Be Good for Shareholders and a Coup for Greenberg Family -- Barrons.com

2025-12-13 00:24; UTC

Įsigijimai, susijungimai, perėmimai

Want a Piece Of SpaceX? -- Barrons.com

2025-12-12 23:49; UTC

Įsigijimai, susijungimai, perėmimai

Intel in Talks to Acquire SambaNova in Deal Valued at $1.6B, Bloomberg Reports, Citing Sources

2025-12-12 22:52; UTC

Rinkos pokalbiai

Nike Expected to Show Further Momentum in 2Q Results -- Market Talk

2025-12-12 22:32; UTC

Uždarbis

These Stocks Moved the Most Today: Broadcom, Oracle, Fermi, Tilray, Lululemon, Costco, Netskope, and More -- Barrons.com

2025-12-12 21:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2025-12-12 20:45; UTC

Uždarbis

The Best Dividend ETF for Right Now -- and 2026 -- Barrons.com

2025-12-12 20:41; UTC

Rinkos pokalbiai

Oil Ends Week Lower As Market Frets About Oversupply -- Market Talk

2025-12-12 20:20; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures Post Hefty Weekly Loss -- Market Talk

2025-12-12 19:23; UTC

Uždarbis

Charles Schwab Is Opening New Accounts and Hauling in New Assets Amid Buoyant Stock Market -- Barrons.com

2025-12-12 18:35; UTC

Įsigijimai, susijungimai, perėmimai

PNC Financial Expects to Close FirstBank Deal On or About Jan. 5, Subject to Satisfaction of Customary Closing Conditions

2025-12-12 18:33; UTC

Įsigijimai, susijungimai, perėmimai

PNC Receives Regulatory Approvals For Acquisition Of FirstBank >PNC

2025-12-12 18:31; UTC

Rinkos pokalbiai

U.S. Oil Rig Count Edges Up by 1 to 414 -- Market Talk

2025-12-12 17:49; UTC

Uždarbis

Tariffs Mean Costco Has Fewer Product Types This Holiday. But It Has Plenty of Pies. -- WSJ

2025-12-12 17:34; UTC

Įsigijimai, susijungimai, perėmimai

Orange: Closing Subject to Customary Regulatory Approvals, Other Closing Conditions

2025-12-12 17:33; UTC

Įsigijimai, susijungimai, perėmimai

Orange: Closing of the Transaction Is Expected in the First Half of 2026

2025-12-12 17:33; UTC

Įsigijimai, susijungimai, perėmimai

Orange: Agreement Confirms the Non-Binding Agreement That Was Previously Announced Oct. 31

2025-12-12 17:32; UTC

Įsigijimai, susijungimai, perėmimai

Orange: MasOrange Is Spain's Leading Operator in Terms of Customer Base

2025-12-12 17:31; UTC

Įsigijimai, susijungimai, perėmimai

Orange to Buy the Stake for EU4.25B in Cash

2025-12-12 17:24; UTC

Rinkos pokalbiai

Argentina Predicts Record Wheat Crop -- Market Talk

2025-12-12 17:20; UTC

Rinkos pokalbiai

Uždarbis

Tech, Media & Telecom Roundup: Market Talk

2025-12-12 17:20; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2025-12-12 17:18; UTC

Rinkos pokalbiai

Uždarbis

Broadcom, Oracle Investor Reactions Show High Bar for AI Cos. -- Market Talk

2025-12-12 17:09; UTC

Rinkos pokalbiai

Broadcom Investors Were Primed to Sell Shares -- Market Talk

2025-12-12 17:09; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2025-12-12 16:47; UTC

Rinkos pokalbiai

Broadcom's Margins Expected to Narrow Due to AI Revenue -- Market Talk

Akcijų palyginimas

Kainos pokytis

Actinium Pharmaceuticals Inc Prognozė

Kainos tikslas

By TipRanks

297.35% į viršų

12 mėnesių prognozė

Vidutinis 6 USD 297.35%

Aukščiausias 9 USD

Žemiausias 4 USD

Remiantis 3 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Actinium Pharmaceuticals Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

3 ratings

Pirkti

Laikyti

Parduoti

Remiantis 3 analitikų, pateikusių Actinium Pharmaceuticals Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Actinium Pharmaceuticals Inc

Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). The company focuses on advancing its development for product candidate Actimab-A, a therapeutic agent that has demonstrated potential activity in r/r AML patients. In addition, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies. Its Iomab-ACT, a next generation conditioning candidate, is being developed for improving patient access and outcomes for curative cell and gene therapies. Further, the company's research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company holds approximately 235 patents and patent applications, including various patents related to the manufacture of the isotope Ac-225 in a cyclotron. The company is based in New York, New York.